Successful Medical Treatment Using Tolvaptan of Ventricular Septal Rupture Following Myocardial Infarction

Kazushi Terada, Kensuke Takagi, Itsuro Morishima and Hideyuki Tsuboi

Abstract:
Although improved treatments for acute myocardial infarction (AMI) have considerably reduced the mortality of AMI in the past two decades, the treatment for ventricular septal rupture (VSR)-a rare but life-threatening mechanical complication of AMI-still remains quite challenging. We herein describe the case of a high-surgical-risk patient with VSR after AMI who was successfully treated using tolvaptan (a novel V2-receptor antagonist) without any mechanical support.

Key words: acute myocardial infarction, ventricular septal rupture, Tolvaptan, heart failure

(Intern Med 56: 2435-2439, 2017)
(DOI: 10.2169/internalmedicine.8402-16)

Introduction
The effectiveness of percutaneous coronary intervention and advances in adjunctive pharmacotherapies for the treatment of acute myocardial infarction (AMI) have considerably reduced the mortality associated with AMI in the past two decades (1, 2). However, treatment for ventricular septal rupture (VSR)-a rare but life-threatening mechanical complication of AMI - still remains extremely challenging.

The mortality associated with VSR generally remains high, but it varies (from 19-64%) when surgical repair is performed. In contrast, the mortality consistently reaches 90-95% when VSR is treated conservatively (3). Although delaying surgery in stable patients with VSR may provide better results, conventional medical therapy with such drugs as furosemide, carperitide, and dobutamine is usually futile. Therefore, until now, surgical repair using full mechanical support has been considered the sole option (3). We herein describe the case of a high-surgical-risk patient with VSR after AMI who was successfully treated using tolvaptan (a novel V2-receptor antagonist) without any mechanical support.

Case Report
A 78-year-old man was taken to the emergency room because he had presented with continued general fatigue and shortness of breath over the previous 2 weeks following an episode of chest pain. On examination, he was ill-appearing and febrile with a temperature of 37.5°C. His blood pressure was 78/52 mm Hg, pulse 112/min, respiratory rate of 22/min with an O2 saturation of 91% on room air. A heart exam revealed S3 and a holosystolic murmur was noted. His chest exam revealed decreased breath sounds bilaterally. Chest X-rays showed a distinctive pattern of congestive heart failure (CHF) (Fig. 1A). The laboratory data are shown in Table 1. Moreover, a coronary angiogram was immediately acquired as the electrocardiogram demonstrated inferior Q wave and ST elevation (Fig. 1B). The coronary angiogram showed no significant stenosis of the left coronary artery (Fig. 1C) and the subtotal occlusion of the right coronary artery (Fig. 1D), which was successfully treated by the implantation of a bare metal stent (Fig. 1E). After recanalization, transthoracic echocardiography (TTE) showed a preserved left ventricular function and moderate pulmonary artery hypertension with moderate tricuspid regurgitation. Furthermore, TTE revealed aneurysmal dilatation in the inferior and septal myocardial segment concomitant with 4.2 mm of VSR (Fig. 2A, B). The findings on TTE are shown in Table 2. To improve the congestion, carperitide was administered at an initial dose of 0.1 μg/kg/min, and furosemide 20 mg was administered twice a day. However, as hemodynamic instability frequently occurred, repeated saline
At 6 days after admission, tolvaptan 7.5 mg was introduced because of hemodynamic instability and increased pleural effusion. The administration of tolvaptan dramatically increased the patient’s urinary output, thus reducing the pleural effusion.

Table 1. Laboratory Data at Admission.

|        |       |       |       |
|--------|-------|-------|-------|
| AST    | 54 IU/L | K     | 3.8 mEq/L |
| ALT    | 71 IU/L | CL    | 99 mEq/L  |
| r-GTP  | 17 IU/L | CA    | 8.1 mg/dL  |
| T-BIL  | 1.4 mg/dL | BS | 169 mg/dL  |
| ALP    | 189 IU/L | CRP  | 4.68 mg/dL  |
| LDH    | 510 IU/L | WBC  | 6.100 μL |
| CPK    | 288 IU/L | RBC  | 371x10^4 |
| BNP    | 1,069.4 pg/mL | Hb | 12.3 g/dL |
| UA     | 9.4 mg/dL | Pt | 30.3x10^4 |
| UN     | 28.3 mg/dL | PT | 16.4 sec |
| CRE    | 1.03 mg/dL | PT % | 48 % |
| TP     | 5.6 g/dL | PT_INR | 1.44 |
| ALB    | 3.3 g/dL | APTT | 41.1 sec |
| T-CHO  | 157 mg/dL | APTT% | 55 % |
| TG     | 87 mg/dL | D-Dimer | 4.3 μg/mL |
| AMY    | 86 IU/L | CK-MB | 10 IU/L |
| NA     | 134 mEq/L | Toroponin I | 2.672 ng/mL |

At 12 days after admission, cardiac rehabilitation was started due to hemodynamic stability. At 22 days after admission, left and right cardiac catheterization was performed to assess the indications for surgical repair. A coronary angiogram revealed the right coronary artery to have no significant stenosis. Right heart catheterization revealed an elevated pulmonary capillary wedge pressure and a significant oxygen saturation step-up in the right ventricle. Left ventriculography showed a significant left-to-right shunt, and the right ventricle was enhanced in a delayed fashion (Fig. 2C, D). The calculated ratio of the volume of the pulmonary flow and systemic flow was over 6.0. The findings on right and left heart catheterization are shown in Table 3.

Based on these results, surgical repair was considered. However, his state of dementia worsened due to long-term hospitalization; owing to tolvaptan administration, the patient’s hemodynamic stability improved the surgical repair threshold and surgery was therefore no longer required. Finally, he was discharged at 32 days after admission. The chest X-ray changes are illustrated in Fig. 2E-H. Furthermore, the patient’s hemodynamic status and urine volume are summarized in Fig. 3.
Table 2. Findings on Transthoracic Echocardiography at Admission.

| AODs   | 22.6 | mm    |
|--------|------|-------|
| LAD    | 33.7 | mm    |
| IVST   | 7.4  | mm    |
| PWT    | 5.9  | mm    |
| LVDD   | 51.0 | mm    |
| LVEDV  | 162.1| mL    |
| LVESV  | 77.1 | mL    |
| SV     | 85.0 | mL    |
| EF     | 52   | %     |
| IVC    | 17   | mm    |
| AR     | trivial |
| MR     | trivial |
| TR     | Mild-moderate |
| TR-PG  | 26   | mmHg  |

VSR is a rare but well-known complication after AMI. In the prethrombolytic era, VSR was thought to complicate 1-2% of AMI presentations (1). After percutaneous coronary intervention became a common practice for AMI, however, more contemporary series show it to be increasingly rare, complicating between 0.17 and 0.31% of the patients presenting with AMI (4-6). Therefore, the frequency of VSR has decreased as a result of the wide acceptance of early reperfusion therapy as it prevents extensive myocardial necrosis and preserves the left ventricular function (1, 3-6).

The conventional mechanism of VSR involves coagulation necrosis of the ischemic tissue with neutrophilic infiltration, eventually causing thinning and weakening of the septal myocardium (1). This sub-acute process takes 3-5 days-an interval that likely accounts for the traditional timing reported in the early surgical literature. It has recently been proposed that a rupture occurring within 24 hours of presentation is more likely due to dissection of an intramural hematoma or a hemorrhage in the ischemic myocardium (3).

When reperfusion therapy is delayed, then perfusion therapy may lead to myocardial hemorrhage and dissection in the zone of necrotic myocardium, subsequently resulting in a worsening VSR. Therefore, whether reperfusion therapy should be performed in patients with delayed MI still remains controversial. However, this patient was treated using
a bare-metal stent to improve hemodynamic stability, although 2 weeks had already passed after the onset of AMI. Although the use of IABP (intra-aortic balloon pump) has been suggested in this setting (3), our patient could not tolerate the continuous use of IABP because of his moderate dementia. Despite advances in pharmacotherapies, coronary intervention, and surgical techniques, the mortality of patients treated with a surgical repair of VSR remains high (3). The most important predictors of early mortality are reported to be the deterioration of patient’s condition before surgical repair and cardiogenic shock on admission. As conservative therapy is associated with an extremely high mortality rate of 94-100%, the timing of surgical repair is critical. It was previously reported that the patients undergoing an early operation for VSR have a more adverse outcome compared with those undergoing late surgery (3). Society of Thoracic Surgeons data showed that patients who underwent surgery within 7 days of presentation had a 54.1% mortality compared with 18.4% mortality if repair was delayed until after 7 days. Mortality was highest (60%) in patients who underwent operation in the first 24 hours, consistent with other investigators (7). Thus, adjunctive pharmacotherapies are important to delay surgical repair. The goals of immediate management include maintaining the coronary artery blood flow, a reduction of systemic vascular resistance with the aim of left-to-right shunt reduction, and maintaining the cardiac output and mean arterial blood pressure to ensure adequate end-organ perfusion. Among the common pharmacotherapies, tolvaptan (a drug that exerts aquaretic effects by blocking the V2 receptor in the renal collecting ducts and consequently results in the inhibition of water reabsorption) may potentially benefit such patients. According to experts, tolvaptan is recognized as the only novel agent tested in pa-

Table 3. Findings on Left and Right Cardiac Catheterization.

|                | SVC | RA | Main PA | Right PA | PCW | RV | LV | LVEDP | Aorta | EF | LVEDV | LVESV | CO  |
|----------------|-----|----|---------|----------|-----|----|----|-------|-------|----|-------|-------|-----|
|                | 0-14 (7) | 0-16 (8) | 15-42 (25) | 12-39 (24) | 20-39 (20) | 0-38 (19) | 4-70 (34) | 12 mm Hg | 52-74 (62) | 51 | 121 mL | 59 mL | 4.9 L/min |
| Na            | 134 | 137 | 140 | 141 | 138 | 140 | 136 | 10 | 97 | 91 | 94 | 91 | 92 | 92 | 93 | 93 | 94 | 96 | 96 | 96 | 97 |
| O2            | 10L | 10L | 10L | 10L | 10L | 10L | 10L | 8L | 5L | 3L | 3L | 2L |
| SpO2          | 97% | 91% | 94% | 91% | 92% | 92% | 93% | 93% | 94% | 96% | 96% | 97% |
| MAP           | 140 | 120 | 100 | 80 | 60 | 40 | 20 | 0 | 140 | 120 | 100 | 80 | 60 | 40 | 20 | 0 |
| HR            | 205 | 200 | 150 | 100 | 80 | 60 | 40 | 20 | 0 | 140 | 120 | 100 | 80 | 60 | 40 | 20 | 0 |

SVC: superior vena cava; RA: right atrium; PA: pulmonary artery; PCW: pulmonary capillary wedge pressure; RV: right ventricle; LV: left ventricle; LVEDP: left ventricular end-diastolic pressure; EF: ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; CO: cardiac output
tients hospitalized for acute CHF syndrome to reach short-term efficacy without causing deleterious side effects (8). Recently, Jujo et al. demonstrated that the initiation of tolvaptan therapy in acute CHF patients exerted potent dehydration effects and preserved the renal function and the renin-angiotensin-aldosterone system without any adverse effects as compared to furosemide therapy (9). Furthermore, Suzuki et al. revealed that less adverse events, such as worsening heart failure and hypotension requiring drug discontinuation, were observed in the tolvaptan group as compared to carperitide (10). Therefore, tolvaptan has a potential to reduce the patient’s edema, improve dyspnea, correct hyponatremia, and to be well-tolerated without adversely affecting the blood pressure, heart rate, electrolyte levels, or renal function when combined with standard therapy (11). Indeed, tolvaptan can be an effective and safe option, particularly in patients with VSR with low cardiac function and low blood pressure. Concomitant with a conventional approach, tolvaptan can help improve congestive heart failure in these cases, and may thus have the potential to become a groundbreaking treatment.

The authors state that they have no Conflict of Interest (COI).

References

1. Birnbaum Y, Fishbein MC, Blanche C, Siegel RJ. Ventricular septal rupture after acute myocardial infarction. N Engl J Med 347: 1426-1432, 2002.
2. Moore CA, Nygaard TW, Kaiser DL, Cooper AA, Gibson RS. Postinfarction ventricular septal rupture: the importance of location of infarction and right ventricular function in determining survival. Circulation 74: 45-55, 1986.
3. Jones BM, Kapadia SR, Smedira NG, et al. Ventricular septal rupture complicating acute myocardial infarction: a contemporary review. Eur Heart J 35: 2060-2068, 2014.
4. Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation 101: 27-32, 2000.
5. Lopez-Sendon J, Gurfinke EP, Lopez de Sa E, et al. Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J 31: 1449-1456, 2010.
6. French JK, Hellkamp AS, Armstrong PW, et al. Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). Am J Cardiol 105: 59-63, 2010.
7. Papalexopoulou N, Young CP, Attia RQ. What is the best timing of surgery in patients with post-infarct ventricular septal rupture? Interact Cardiovasc Thorac Surg 16: 193-196, 2013.
8. Ambrosy A, Goldsmith SR, Gheorghiade M. Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin Pharmacother 12: 961-976, 2011.
9. Jujo K, Saito K, Ishida I, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3: 177-188, 2016.
10. Suzuki S, Yoshihisa A, Yamaki T, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol 53: 1277-1285, 2013.
11. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107: 2690-2696, 2003.